alexa Detection of Minimal Residual Disease in Childhood B-Ac
ISSN: 2329-8790

Journal of Hematology & Thromboembolic Diseases
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Detection of Minimal Residual Disease in Childhood B-Acute Lymphoblastic Leukemia by 4-Color Flow Cytometry

Ahmad Baraka1*, Laila M Sherief2, Nagla M Kamal3 and Shereen El Shorbagy4

1Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt

2Department of Pediatric, Faculty of Medicine, Zagazig University, Egypt

3Department of Pediatric, Faculty of Medicine, Cairo University, Egypt

4Department of Medical Oncology, Faculty of Medicine, Zagazig University, Egypt

*Corresponding Author:
Dr Ahmad Baraka
Department of Clinical Pathology
Faculty of Medicine
Zagazig University , Egypt
Tel: 01005648997
E-mail: [email protected]

Received date: December 02, 2016; Accepted date: January 20, 2017; Published date: January 27, 2017

Citation: Baraka A, Sherief ML, Kamal MN, El shorbagy S (2017) Detection of Minimal Residual Disease in Childhood B-Acute Lymphoblastic Leukemia by 4-Color Flow Cytometry. J Hematol Thrombo Dis 5:260. doi:10.4172/2329-8790.1000260

Copyright: © 2016 Baraka A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Monitoring of minimal residual disease (MRD) is today considered the most powerful predictor of outcome in acute leukemias, including acute lymphoblastic leukemia (ALL). The study aimed to determine whether panel of antibodies combination are more suitable than others for detection of MRD in Childhood B-lineage ALL. Eighty four (84) patients of ALL (B-lineage subtype) were enrolled in this study. Normal template for B. Cell precursors were been established in 15 control Patients by using 4 panels of monoclonal Abs (Mo Abs), {CD22, CD45, CD58 and CD97 in combination with CD10, CD19, CD34}. At diagnosis CD22 having the lowest incidence expression between the patients in 50% only, but CD45, CD58, and CD97 were expressed in 80.9%, 52.3% and 92.8% respectively. Analysis of MRD was performed for each Mo Abs combination at day 0 and day 14 post induction of chemotherapy by 4-color flow cytometer (FCM). The incidence of MRD were 61.9%, 70.6%, 60.0% and 55.5% for CD22,CD45,CD58 and CD97 respectively. Seventy-six from total 84 cases studied (90.0%) had at least one LAIP. Of these, 22 (29.0%) had only one LAIP and 54 cases (71.0%) had ≥ 2 LAIPS
Conclusion: In the B-ALL patients (CD10/CD19/CD34/CD45)+ and (CD10/CD19/CD34/CD97)+, represented the highest incidence markers expression of leukemic cells with a significant correlation with blasts count, so it's the more specific for MRD detection.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords